Skip to main content

Table 5 Adverse effects of MM-398.

From: Cancer nanomedicine: a review of recent success in drug delivery

  Nanoliposomal irinotecan plus fluorouracil and folinic acid combination therapy (n = 117) Nanoliposomal irinotecan monotherapy (n = 147) Fluorouracil and folinic acid control (n = 134)
Any grade Grades 3–4 Any grade Grades 3–4 Any grade Grades 3–4
Diarrhoea 69 (59%) 15 (13%) 103 (70%) 31 (21%) 35 (26%) 6 (4%)
Vomiting 61 (52%) 13 (11%) 80 (54%) 20 (14%) 35 (26%) 4 (3%)
Nausea 60 (51%) 9 (8%) 89 (61%) 8 (5%) 46 (34%) 4 (3%)
Decreased appetite 52 (44%) 5 (4%) 72 (49%) 13 (19%) 43 (32%) 3 (2%)
Fatigue 47 (40%) 16 (14%) 54 (37%) 9 (6%) 37 (28%) 5 (4%)
Neutropenia* 46 (39%) 32 (27%) 37 (25%) 22 (15%) 7 (5%) 2 (1%)
Anaemia 44 (38%) 11 (9%) 48 (33%) 16 (11%) 31 (23%) 9 (7%)
Hypokalemia 14 (12%) 4 (3%) 32 (22%) 17 (12%) 12 (9%) 3 (2%)
  1. Data are number of patients (%). The table shows grade 3 and 4 adverse events reported in ≥ 5% of patients whose treatment included nanoliposomal irinotecan with ≥ 2% incidence versus fluorouracil and folinic acid
  2. * Includes agranulocytosis, febrile neutropenia, granulocytopenia, neutropenia, neutropenic sepsis, decreased neutrophil count, and pancytopenia